“Continuing our mission to serve transplant patients, we achieved our sixth consecutive quarter of testing services volume growth in the fourth quarter. Momentum continued to build for kidney surveillance testing throughout the quarter, and we completed our sales and marketing expansion by about 30 professionals. We are well-positioned for another successful year of growth in 2025 and on pace to achieve our targets of $500 million in revenue and 20% adjusted EBITDA in 2027,” said John Hanna, CareDx (CDNA) President and CEO.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener